The Joint Committee on Vaccination and Immunisation (JCVI), the expert committee that advises Ministers on immunisation related issues, considered the safety of the human papillomavirus (HPV) vaccine in June 2015. It considered reports made to the Medicines and Healthcare products Regulatory Agency and also published literature. It concluded that it had no concerns about the safety of the HPV vaccine. The JCVI strongly supported continued use of the HPV vaccine to prevent infection with HPV and reduce cases of cervical cancer and other HPV associated cancers. The minutes of the meeting will be published later in the year.
European regulators are aware of the reports emerging from Denmark, including reports of Postural Orthostatic Tachycardia Syndrome, and these remain under review. At this time the evidence does not support a causative link between HPV vaccination and Postural Orthostatic Tachycardia Syndrome.
The safety of HPV vaccines remain under continual review and appropriate action will be taken if any important new risks are confirmed.